Overview

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Treatments:
Carbamazepine
Oxcarbazepine